Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, P.R. China.
Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P.R. China.
J Dermatolog Treat. 2023 Dec;34(1):2229466. doi: 10.1080/09546634.2023.2229466.
Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form of uveitis, in her left eye 2 weeks after starting dupilumab treatment, which improved after reducing the dose, without discontinuing dupilumab. The patient also experienced asymptomatic hypereosinophilia, possibly related to dupilumab, which was gradually relieved without discontinuation. With the readers, we share our experience in managing uveitis and hypereosinophilia associated with dupilumab, which may be helpful in managing these conditions and avoiding discontinuation of dupilumab.
葡萄膜炎是度普利尤单抗的一种罕见不良反应，通常累及双眼，常导致治疗中断。本文报告了 1 例 28 岁女性，患有特应性皮炎，在开始度普利尤单抗治疗 2 周后左眼新发虹膜睫状体炎（葡萄膜炎的一种类型），减少剂量后病情改善，无需中断度普利尤单抗治疗。患者还出现无症状性嗜酸性粒细胞增多症，可能与度普利尤单抗相关，逐渐缓解而无需停药。与读者分享我们在管理与度普利尤单抗相关的葡萄膜炎和嗜酸性粒细胞增多症方面的经验，这可能有助于管理这些疾病并避免中断度普利尤单抗治疗。
